Generation Bio CO Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Atlas Venture entities have jointly filed a Schedule 13G, reporting 0% beneficial ownership of Generation Bio Co. common stock as of March 31, 2026.
T. Rowe Price Associates, Inc. has filed an amendment to its Schedule 13G, reporting a 3.1% beneficial ownership in Generation Bio Co. common stock.
Renaissance Technologies LLC and its parent company have reported a 4.27% beneficial ownership stake in Generation Bio Co. as of December 31, 2025.
Baslake Partners, LP and its affiliates have reported a complete divestment of their beneficial ownership in Generation Bio Co., now holding 0% of the common stock.
Baslake Partners, LP, along with its management entity and managing member, has reported a 5.2% beneficial ownership stake in Generation Bio Co. as of February 5, 2026.
SymBiosis Capital Partners, LLC has disclosed a 6.3% beneficial ownership stake in Generation Bio Co., holding 421,926 shares of common stock.
SymBiosis Capital Partners, LLC has reported a 6.3% beneficial ownership stake in Generation Bio Co.'s common stock as of September 30, 2025.
T. Rowe Price Associates, Inc. has reported an 8.6% beneficial ownership stake in Generation Bio Co. common stock as of September 30, 2025.
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a 5.11% beneficial ownership stake in Generation Bio Co. as of July 1, 2025.
T. Rowe Price Associates, Inc. has increased its beneficial ownership in Generation Bio Co. to 12.6% of common stock, holding over 8.4 million shares.
FMR LLC and Abigail P. Johnson have updated their beneficial ownership in Generation Bio to 3.5% of the class, as disclosed in a recent Schedule 13G/A filing.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 1.7% passive beneficial ownership stake in Generation Bio Co., though the filing contains conflicting information regarding a subsidiary's ownership and an unusual future event date.
FMR LLC and its Chairman and CEO, Abigail P. Johnson, have reported a beneficial ownership of 6.9% of Generation Bio's common stock as of December 31, 2024.